Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis

Chee Kian Chew; Bart Clarke

doi:10.1016/j.maturitas.2016.12.003

Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis

Chee Kian Chew, Bart Clarke

Endocrinology, Diabetes, Metabolism, and Nutrition

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1–34 [rhPTH (1–34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1–34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.

Original language	English (US)
Pages (from-to)	53-60
Number of pages	8
Journal	Maturitas
Volume	97
DOIs	https://doi.org/10.1016/j.maturitas.2016.12.003
State	Published - Mar 1 2017

Keywords

Abaloparatide
Anabolic agents
Fractures
Osteoporosis
PTHrP 1–34

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)
Obstetrics and Gynecology

Access to Document

10.1016/j.maturitas.2016.12.003

Cite this

@article{c5768a1efdf748b5b6ba90a6ea30d7e8,

title = "Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis",

abstract = "The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1–34 [rhPTH (1–34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1–34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.",

keywords = "Abaloparatide, Anabolic agents, Fractures, Osteoporosis, PTHrP 1–34",

author = "Chew, {Chee Kian} and Bart Clarke",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.maturitas.2016.12.003",

language = "English (US)",

volume = "97",

pages = "53--60",

journal = "Maturitas",

issn = "0378-5122",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Abaloparatide

T2 - Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis

AU - Chew, Chee Kian

AU - Clarke, Bart

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1–34 [rhPTH (1–34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1–34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.

AB - The treatment of osteoporosis is generally either by inhibition of bone resorption with antiresorptive agents or by stimulation of bone formation with anabolic agents. Currently, teriparatide (recombinant human parathyroid hormone 1–34 [rhPTH (1–34)]) is the only available approved anabolic agent in the U.S. Other anabolic agents are under investigation however. Abaloparatide is recombinant human parathyroid hormone-related peptide 1–34. This agent is an anabolic agent that appears more potent than teriparatide, and it may have more rapid onset of fracture reduction than teriparatide. It is currently undergoing FDA review, with approval expected in 2017.

KW - Abaloparatide

KW - Anabolic agents

KW - Fractures

KW - Osteoporosis

KW - PTHrP 1–34

UR - http://www.scopus.com/inward/record.url?scp=85009354130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009354130&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2016.12.003

DO - 10.1016/j.maturitas.2016.12.003

M3 - Review article

C2 - 28159062

AN - SCOPUS:85009354130

VL - 97

SP - 53

EP - 60

JO - Maturitas

JF - Maturitas

SN - 0378-5122

ER -

Abaloparatide: Recombinant human PTHrP (1–34) anabolic therapy for osteoporosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this